Akari Therapeutics, Plc (AKTX) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は London, イギリス. 現CEOは Abizer Gaslightwala.
AKTX を有する IPO日 2014-01-06, 8 名の正社員, に上場 NASDAQ Capital Marke, 時価総額 $4.26M.
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.
